Dataset Information

Biodistribution, dosimetry, and temporal signal-to-noise ratio analyses of normal and cancer uptake of [⁶⁸Ga]Ga-P15-041, a gallium-68 labeled bisphosphonate, from first-in-human studies.

ABSTRACT:

Introduction

[⁶⁸Ga]Ga-P15-041 ([⁶⁸Ga]Ga-HBED-CC-BP) is a novel bone-seeking PET radiotracer that can be generator-produced. We undertook a Phase 0/I clinical trial to assess its potential for imaging bone metastases in prostate cancer including assessment of radiotracer biodistribution and dosimetry.

Methods

Subjects with prostate cancer and known or suspected osseous metastatic disease were enrolled into one of two arms: dosimetry or dynamic. Dosimetry was performed with 6 whole body PET acquisitions and urine collection spanning 3 h; normal organ dosimetry was calculated using OLINDA/EXM. Dynamic imaging included a 60 min acquisition over a site of known or suspected disease followed by two whole body scans. Bootstrapping and subsampling of the acquir

SUBMITTER: Doot RK

PROVIDER: S-EPMC7311273 | biostudies-literature | 2020 Jul - Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Dataset Information

Biodistribution, dosimetry, and temporal signal-to-noise ratio analyses of normal and cancer uptake of [⁶⁸Ga]Ga-P15-041, a gallium-68 labeled bisphosphonate, from first-in-human studies.

Introduction

Methods

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Biodistribution, dosimetry, and temporal signal-to-noise ratio analyses of normal and cancer uptake of [68Ga]Ga-P15-041, a gallium-68 labeled bisphosphonate, from first-in-human studies.

Introduction

Methods

OmicsDI is part of the ELIXIR infrastructure

Tweets

Biodistribution, dosimetry, and temporal signal-to-noise ratio analyses of normal and cancer uptake of [⁶⁸Ga]Ga-P15-041, a gallium-68 labeled bisphosphonate, from first-in-human studies.